Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
24 January 2025
| m 17:15 | Low-grade glioma - null regimens diffhist +20 Jwarner talk contribs (→Regimen) | ||||
| m 17:14 | Vorasidenib (Voranigo) diffhist −649 Jwarner talk contribs (→Diseases for which it is established) | ||||
| m 02:13 | Neuroblastoma diffhist +17 Jwarner talk contribs | ||||
| m 02:04 | Rectal cancer diffhist +93 Jwarner talk contribs | ||||
| m 01:55 | Non-small cell lung cancer diffhist −62 Jwarner talk contribs | ||||
23 January 2025
| 22:42 | Editorial Board diffhist +16 Warner-admin talk contribs | ||||
| m 22:35 | Ovarian cancer diffhist +213 Jwarner talk contribs (→ASCO) | ||||
| m 12:06 | Wilms tumor diffhist −3 Jwarner talk contribs | ||||
|
|
m 12:05 | Myelofibrosis 2 changes history +221 [Jwarner (2×)] | |||
| m |
|
12:05 (cur | prev) +187 Jwarner talk contribs | |||
| m |
|
12:02 (cur | prev) +34 Jwarner talk contribs | |||
| m 11:56 | Pyruvate kinase deficiency diffhist −2 Jwarner talk contribs (→Mitapivat monotherapy) | ||||
| m 11:56 | WHIM syndrome diffhist −2 Jwarner talk contribs (→Mavorixafor monotherapy) | ||||
| m 11:55 | Bladder cancer - historical diffhist −1 Jwarner talk contribs (→Intravesicular Doxorubicin monotherapy) | ||||
22 January 2025
|
|
20:40 | Hepatocellular carcinoma 3 changes history +3,944 [Jwarner (3×)] | |||
| m |
|
20:40 (cur | prev) +61 Jwarner talk contribs (→TACE monotherapy) | |||
| m |
|
20:38 (cur | prev) +1,441 Jwarner talk contribs (→TACE monotherapy) | |||
|
|
16:03 (cur | prev) +2,442 Jwarner talk contribs (→Lenvatinib & TACE) | ||||
|
|
N 13:16 | Datopotamab deruxtecan (Datroway) 2 changes history +1,967 [Jwarner (2×)] | |||
| m |
|
13:16 (cur | prev) +118 Jwarner talk contribs | |||
| N |
|
02:19 (cur | prev) +1,849 Jwarner talk contribs (Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/datopotamab-deruxtecan NCI Drug Dictionary]: An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (calcium signal transducer 2; TROP2; TROP-2; TACSTD2) conjugated, via an enzymatically cleavable tetrapeptide-based linker, to the cytotoxic DNA topoisomerase I inhibitor and exate...") | |||
| 13:16 | Non-small cell lung cancer diffhist +2,889 Jwarner talk contribs (→Docetaxel monotherapy) | ||||
| 13:02 | Multiple myeloma, consolidation and maintenance diffhist +4,622 Jwarner talk contribs (→Lenalidomide monotherapy) | ||||
| N 12:43 | NDMM diffhist +41 Jwarner talk contribs (Redirected page to Multiple myeloma, induction) | ||||
| m 12:37 | Breast cancer, HER2-positive diffhist +1,762 Jwarner talk contribs | ||||
| N 12:24 | Lerociclib (GB-491) diffhist +1,908 Jwarner talk contribs (Created page with "==Mechanism of action== From [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lerociclib NCI Drug Dictionary]: An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, lerociclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S phase transition and leads t...") | ||||
|
|
m 12:19 | Drug index 3 changes history +59 [Jwarner (3×)] | |||
| m |
|
12:19 (cur | prev) +25 Jwarner talk contribs (→L) | |||
| m |
|
02:12 (cur | prev) +72 Jwarner talk contribs (→D) | |||
| m |
|
02:10 (cur | prev) −38 Jwarner talk contribs (→D) | |||
|
|
m 12:03 | Glossary 2 changes history +181 [Jwarner (2×)] | |||
| m |
|
12:03 (cur | prev) +86 Jwarner talk contribs (→2) | |||
| m |
|
12:03 (cur | prev) +95 Jwarner talk contribs (→2) | |||
|
|
12:02 | Breast cancer, ER-positive 8 changes history +9,857 [Jwarner (8×)] | |||
| m |
|
12:02 (cur | prev) +1,330 Jwarner talk contribs (→Fulvestrant monotherapy) | |||
| m |
|
11:51 (cur | prev) +119 Jwarner talk contribs | |||
| m |
|
02:41 (cur | prev) −4 Jwarner talk contribs (→Gemcitabine monotherapy) | |||
| m |
|
02:40 (cur | prev) +1,810 Jwarner talk contribs (→Vinorelbine monotherapy) | |||
| m |
|
02:38 (cur | prev) +1,827 Jwarner talk contribs (→Gemcitabine monotherapy) | |||
| m |
|
02:36 (cur | prev) +1,179 Jwarner talk contribs (→Eribulin monotherapy) | |||
| m |
|
02:35 (cur | prev) +1,527 Jwarner talk contribs (→Capecitabine monotherapy) | |||
|
|
02:32 (cur | prev) +2,069 Jwarner talk contribs (→Elacestrant monotherapy) | ||||
| N 02:21 | Category:Anti-TROP2 antibodies diffhist +49 Jwarner talk contribs (Created page with "Category:Antineoplastic monoclonal antibodies") | ||||
| N 02:20 | Category:Anti-TROP2 antibody-drug conjugates diffhist +72 Jwarner talk contribs (Created page with "Category:Antibody-drug conjugates Category:Anti-TROP2 antibodies") | ||||
| N 02:20 | Category:FDA approved in 2025 diffhist +31 Jwarner talk contribs (Created page with "Category:FDA approved drugs") | ||||
21 January 2025
| m 13:05 | Glossary diffhist +45 Jwarner talk contribs (→T) | ||||
|
|
13:03 | Hepatocellular carcinoma 2 changes history +3,004 [Jwarner (2×)] | |||
| m |
|
13:03 (cur | prev) +813 Jwarner talk contribs (→References) | |||
|
|
13:03 (cur | prev) +2,191 Jwarner talk contribs (→Lenvatinib & TACE) | ||||
| 02:24 | Esophageal squamous cell carcinoma diffhist +6,764 Jwarner talk contribs (→Neoadjuvant induction therapy) | ||||
| m 02:03 | Breast cancer, HER2-low diffhist +56 Jwarner talk contribs | ||||
| N 02:01 | Category:Anti-CD45 antibodies diffhist +49 Jwarner talk contribs (Created page with "Category:Antineoplastic monoclonal antibodies") | ||||
| N 02:01 | Category:Anti-CD45 radioimmunoconjugates diffhist +67 Jwarner talk contribs (Created page with "Category:Radioimmunoconjugate Category:Anti-CD45 antibodies") | ||||
| N 02:01 | Iodine I 131 apamistamab (Iomab-B) diffhist +2,072 Jwarner talk contribs (Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/iodine-i-131-apamistamab NCI Drug Dictionary]: A radioimmunoconjugate consisting of BC8, a murine IgG1 anti-CD45 monoclonal antibody labeled with iodine 131 (I-131), with radioimmunotherapeutic properties. Using monoclonal antibody BC8 as a carrier for I-131 results in the targeted destruction of cells expressing CD45. ==Preliminary data== ''Note: This is not meant to be a...") | ||||
|
|
m 01:55 | Drug index 2 changes history +68 [Jwarner (2×)] | |||
| m |
|
01:55 (cur | prev) +40 Jwarner talk contribs (→I) | |||
| m |
|
01:55 (cur | prev) +28 Jwarner talk contribs (→S) | |||
| m 00:11 | Clear cell renal cell carcinoma - null regimens diffhist +1,135 Jwarner talk contribs (→Placebo) | ||||